STAGE IIIB NON-SMALL CELL LUNG CANCER
Clinical trials for STAGE IIIB NON-SMALL CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new STAGE IIIB NON-SMALL CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for STAGE IIIB NON-SMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a diabetes drug boost lung cancer treatment?
Disease control CompletedThis study looked at whether adding metformin (a common diabetes medicine) to standard chemotherapy and radiation helps people with stage III non-small cell lung cancer live longer without their cancer getting worse. About 170 adults with advanced lung cancer took part. The goal …
Matched conditions: STAGE IIIB NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New combo therapy shows promise for Hard-to-Treat lung cancer
Disease control CompletedThis early-phase study tested a new drug called ONO-7475 combined with the standard targeted therapy osimertinib in 78 people with advanced EGFR-mutated non-small cell lung cancer. The goal was to see if the combination is safe and tolerable. Participants had stage IIIB, IIIC, IV…
Matched conditions: STAGE IIIB NON-SMALL CELL LUNG CANCER
Phase: PHASE1 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New combo therapy for lung cancer shows promise in early trial
Disease control CompletedThis early-phase trial tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy and radiation is safe for people with stage II to IIIB non-small cell lung cancer. Twenty-three participants received the combination to find the best dose and check for sid…
Matched conditions: STAGE IIIB NON-SMALL CELL LUNG CANCER
Phase: PHASE1 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New combo therapy for lung cancer shows promise in early trial
Disease control CompletedThis study tested a new treatment approach for people with inoperable non-small cell lung cancer. It combined MRI-guided radiation therapy with chemotherapy and an immunotherapy drug called durvalumab. The goal was to see if this combination is safe and effective at controlling t…
Matched conditions: STAGE IIIB NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New combo therapy shows promise for hard-to-treat lung cancer
Disease control CompletedThis study tested a combination of a cancer vaccine (TG4010) and an immunotherapy drug (nivolumab) in 13 people with advanced non-small cell lung cancer who had already received other treatments. The goal was to see if the combination could shrink tumors or stop them from growing…
Matched conditions: STAGE IIIB NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Megan Daly, MD • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New combo therapy shows promise against tough cancers
Disease control CompletedThis study tested a combination of two drugs—sEphB4-HSA and pembrolizumab—in 42 people with advanced non-small cell lung cancer or head & neck cancer that had spread or returned. The goal was to see if the combo could shrink tumors better than standard treatments. Participants ha…
Matched conditions: STAGE IIIB NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Old arthritis drug paired with immune suppressant shows promise against tough lung cancers
Disease control CompletedThis study tested two drugs—auranofin (originally for arthritis) and sirolimus (an immune suppressant)—in 29 people with advanced or recurrent lung cancer who had no standard options left. The goal was to find the safest dose and see if the combination could slow cancer growth. T…
Matched conditions: STAGE IIIB NON-SMALL CELL LUNG CANCER
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 26, 2026 13:58 UTC